

# J2329

## The permanent J-code for BRIUMVI<sup>®</sup> is now available For dates of service on or after July 1, 2023

For patients who receive BRIUMVI on or after July 1, 2023, use the BRIUMVI permanent J-Code J2329. The permanent J-Code identifies BRIUMVI for coding specificity and claims submission.<sup>1-3</sup>

|                                       |   |
|---------------------------------------|---|
| <b>J-code description<sup>1</sup></b> | <b>J2329, Injection, ublituximab-xiiy, 1 mg</b>           |
| <b>Package strength<sup>4</sup></b>   | <b>One 150 mg/6 mL vial</b>                               |
| <b>Billing units<sup>1</sup></b>      | <b>Day 1 Dose: 150<br/>All other doses: 450</b>           |
| <b>NDC number<sup>4</sup></b>         | <b>10-digit: 73150-150-06<br/>11-digit: 73150-0150-06</b> |

**The permanent J-code replaces the miscellaneous HCPCS (Level II) codes  
if BRIUMVI is administered on or after July 1, 2023**

The information in this resource is provided as a reference only and may be relevant when billing for BRIUMVI and its administration. This information is subject to change. Payer coding requirements may vary or change over time, so it is important to regularly check with each payer as to payer-specific requirements. The information available here is not intended to be conclusive nor exhaustive and is not intended to replace the guidance of a qualified professional advisor. TG and its agents make no warranties or guarantees, expressed or implied, concerning the accuracy or appropriateness of this information for your particular use given the frequent changes in public and private payer billing. The use of this information does not guarantee payment or that any payment received will cover your costs.

## Permanent J-code checklist

- If your patient's infusion date is before July 1, 2023, submit documentation (e.g., PA, claims form) to the health plan using the miscellaneous codes
- If your patient's infusion date is on or after July 1, 2023, submit documentation (e.g., PA, claims form) to the health plan using the BRIUMVI permanent J-Code, J2329
- Update your practice's or institution's EMR/EHR system and billing software to reflect the permanent J-Code, J2329, with 150 units for the Day 1 dose and 450 units for all other doses
- Understand your payer contracts and how they may be affected by the BRIUMVI permanent J-Code, J2329

**If you have questions about the BRIUMVI permanent J-code J2329, contact your local Access and Reimbursement Manager or BRIUMVI Patient Support by calling 1-833-BRIUMVI (1-833-274-8684), Monday-Friday 8 AM to 8 PM EST**

REFERENCES: Centers for Medicare & Medicaid Services (CMS). Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Recommendations First Quarter, 2023 HCPCS Coding Cycle. <https://www.cms.gov/files/document/2023-hcpcs-applicationsummary-quarter-1-2023-drugs-and-biologicals-updated-04/28/2023.pdf>. Accessed May 10, 2023. 2. CMS. HCPCS Coding Questions. [https://www.cms.gov/medicare/coding/medhcpcsgeninfo/hcpcs\\_coding\\_questions](https://www.cms.gov/medicare/coding/medhcpcsgeninfo/hcpcs_coding_questions). Updated February 17, 2023. Accessed May 10, 2023. 3. Nusgart M. HCPCS Coding: An Integral Part of Your Reimbursement Strategy. *Adv Wound Care* (New Rochelle). 2013;2(10):576-582. doi:10.1089/wound.2013.0484. 4. BRIUMVI [prescribing information]. New York, NY: TG Therapeutics, Inc.; 2022.